Navigation Links
Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
Date:2/11/2011

n with the existing standard of care drugs. We also believe that CTS-1027 may be an ideal candidate for use in combination with new antiviral drugs in future all oral treatments for HCV," said Steven J. Mento Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... JUPITER, Fla. , May 21, 2013  BioRestorative ... a life sciences company focused on developing stem cell ... Mark Weinreb , its President and CEO, ... The conference will be held on Thursday, ... at 109 E 42nd Street in New York City.  ...
(Date:5/21/2013)... 2013 Ceregene, Inc. today announced additional ... double-blind, randomized, controlled Phase 2b clinical study of ... designed to deliver the neurotrophic factor neurturin, for ... robust response to CERE-120 in Parkinson,s patients diagnosed ... those diagnosed 10 years or more (p<.005), as ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... Nov. 18, 2010 The Pharmacy Technician ... Melissa Murer Corrigan, will serve as the 2011 president ... be installed at the ICE Annual Education Conference on ... organization that provides educational, networking and advocacy resources for ...
... 2010 Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... Application ("MAA") seeking approval for Pixuvri™ (pixantrone dimaleate) ... relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") was ... Medicines Agency ("EMA"). Validation indicates that the application ...
Cached Medicine Technology:Melissa Murer Corrigan to Serve as 2011 ICE President 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3
(Date:5/21/2013)... May 21 (HealthDay News) -- Urban elementary school ... experience sleep problems and suffer academically, new research ... aged seven to nine, we found that compromised ... and impaired academic performance," said study author ... human behavior at Brown University,s Alpert Medical School ...
(Date:5/21/2013)... Minn. Positively charged gold nanoparticles are usually ... to avoid nanoparticle toxicity. Mayo Clinic researchers found ... nanoparticles effective against ovarian cancer cells. The discovery ... the Journal of Biological Chemistry ., "This ... cancer cells by preventing the cell death or ...
(Date:5/21/2013)... May 21, 2013 Representatives with Hammerhead Bicycles ... a success that the company has achieved its overall goal ... day one was to move Hammerhead Bicycles from a house ... President Scott Robertson. , Robertson explained that the bike shop ... to exclusively focus on all things 29er and 650b. ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two-thirds of ... non-small cell lung cancer reported that they engage in ... medicine use, according to new findings from the ... Kantar Health . The research will be presented ... (International Society for Pharmacoeconomics and Outcomes Research) in New ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3
... (ASX: PGL; Nasdaq: PGLA) announced today that its ... status by the U.S. Food,and Drug Administration (FDA). ... 88 for the prevention of tumor recurrence following ... primary liver,cancer). Under the FDA Modernization Act ...
... Urgent Health Problems Report Highest Satisfaction When Seen by ... , Patient satisfaction with after-hours care for an urgent ... physician or their physicians after-hours clinic, compared with a ... services. According to a survey of 1,227 patients from ...
... seldom questioned, study found , , MONDAY, Sept. 24 (HealthDay ... some of their neediest patients, a new study suggests ... that raise suicide risk. , U.S. researchers recruited ... showing signs of depression or a similar disorder. , ...
... for her contributions to kidney ... ... a nationwide patient advocacy group comprised of more than 20,000,dialysis and pre-dialysis ... Entitled, Celebrating the Empowerment of,Kidney Patients, the event brought together dialysis patients ...
... N.C., Sept. 24 SalesForce4Hire(R), a provider of,custom ... Science industries,today announced the opening of its new ... allows SalesForce4Hire to expand its custom sales focus ... size of its sales,support call center. This new ...
... Robust Clinical Data Package Provided in NDA Demonstrates ... Safety of Once-Daily Tramadol Formulation, LAVAL, QC, Sept. ... announced that is has requested a meeting with the ... Drug,Application (NDA) for its once-daily formulation of tramadol. Based ...
Cached Medicine News:Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:September/October 2007 Annals of Family Medicine tip sheet 2Health News:September/October 2007 Annals of Family Medicine tip sheet 3Health News:September/October 2007 Annals of Family Medicine tip sheet 4Health News:September/October 2007 Annals of Family Medicine tip sheet 5Health News:September/October 2007 Annals of Family Medicine tip sheet 6Health News:September/October 2007 Annals of Family Medicine tip sheet 7Health News:Doctors Often Fail to Spot Suicidal Patients 2Health News:Doctors Often Fail to Spot Suicidal Patients 3Health News:Nation's Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care 2Health News:Nation's Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care 3Health News:SalesForce4Hire Opens New Office 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 3
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
... is a quantitative microplate enzyme immunoassay that detects ... have very small amounts of NMP22 protein in ... is often elevated in the urine of patients ... the disease. The use of the NMP22 protein ...
Medicine Products: